Chemomab's Nebokitug Shows Potential for Treating Systemic Sclerosis

Chemomab Therapeutics announced a new scientific presentation that confirms the potential of nebokitug as a treatment for systemic sclerosis. The data will be presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity. The presentation reinforces Chemomab's belief that nebokitug has substantial potential as a treatment for the condition, which lacks disease-modifying therapies.

Systemic sclerosis (SSc), an autoimmune disease characterized by microvascular injury and extensive tissue fibrosis, remains a significant unmet medical need. With no approved disease-modifying therapies available, the search for effective treatments continues. A recent scientific presentation by Chemomab Therapeutics at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025) has added to the growing body of evidence supporting the potential of nebokitug (CM-101) as a novel treatment for SSc [1].

Nebokitug is a first-in-class monoclonal antibody that targets the soluble protein CCL24. Preclinical studies have shown that blocking CCL24 reduces inflammatory and fibrotic injury to the lung, skin, and vasculature, which are hallmarks of SSc pathology [1]. In an investigator-sponsored study, treatment with nebokitug induced strong and rapid reductions in inflammatory biomarkers in patients with acute lung injury, a relevant model for the type of lung damage seen in SSc patients [1].

The new data presented at CORA 2025 further reinforces Chemomab's belief in nebokitug's potential as a treatment for SSc. The company has an open U.S. IND for a Phase 2 trial of nebokitug in SSc.

Adi Mor, PhD, co-founder, CEO, and CSO of Chemomab, commented on the significance of the new data, stating, "These results add to the extensive body of preclinical evidence that CCL24 is a key driver of the skin, lung, and vascular manifestations of this disabling condition. We believe that nebokitug has substantial potential as a treatment for SSc based on multiple preclinical and patient sample studies and the positive results from our Phase 2 PSC trial" [1].

References:

[1] GlobeNewswire. New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis. March 06, 2025. https://www.globenewswire.com/news-release/2025/03/06/3038138/0/en/New-Data-Presented-at-CORA-2025-Conference-Highlights-Clinical-Potential-of-Chemomab-s-Nebokitug-in-Systemic-Sclerosis.html.